tiprankstipranks
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990)
:6990
Hong Kong Market
6990
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
RESEARCH TOOLSreports
Want to see HK:6990 full AI Analyst Report?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

6990 Analyst Ratings

Strong Buy
12Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Sichuan
Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

6990 Stock 12 Month Forecast

Average Price Target

HK$547.77
▲(5.34% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H in the last 3 months. The average price target is HK$547.77 with a high forecast of HK$625.00 and a low forecast of HK$507.11. The average price target represents a 5.34% change from the last price of HK$520.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"318":"HK$318","395":"HK$395","472":"HK$472","549":"HK$549","626":"HK$626"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$625.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":547.7666666666668,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$547.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":507.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$507.11</span>\n  </div></div>","useHTML":true}}],"tickPositions":[318,395,472,549,626],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,435.4,449.9846153846154,464.5692307692307,479.15384615384613,493.73846153846154,508.3230769230769,522.9076923076923,537.4923076923077,552.0769230769231,566.6615384615384,581.2461538461539,595.8307692307692,610.4153846153846,{"y":625,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,435.4,444.04358974358973,452.6871794871795,461.33076923076925,469.974358974359,478.61794871794876,487.2615384615385,495.9051282051282,504.54871794871804,513.1923076923077,521.8358974358976,530.4794871794873,539.1230769230771,{"y":547.7666666666668,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,435.4,440.9161538461538,446.4323076923077,451.9484615384615,457.4646153846154,462.9807692307692,468.49692307692305,474.01307692307694,479.52923076923076,485.0453846153846,490.5615384615385,496.0776923076923,501.5938461538462,{"y":507.11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":319,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":405.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":486,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":514,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":448,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":440,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":392.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":375.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":497,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":469.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":435.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$625.00Average Price TargetHK$547.77Lowest Price TargetHK$507.11
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Nomura Analyst forecast on HK:6990
Unknown Analyst
Nomura
Not Ranked
Nomura
HK$544.42
Buy
4.70%
Upside
Reiterated
05/22/26
Citic Securities Analyst forecast on HK:6990
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$544
Buy
4.62%
Upside
Reiterated
05/22/26
UBS Analyst forecast on HK:6990
Unknown Analyst
UBS
Not Ranked
UBS
HK$625
Buy
20.19%
Upside
Reiterated
05/21/26
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Receives a Buy from UBS
Shenwan Hongyuan Analyst forecast on HK:6990
Unknown Analyst
Shenwan Hongyuan
Not Ranked
Shenwan Hongyuan
HK$560
Buy
7.69%
Upside
Reiterated
03/26/26
Shenwan Hongyuan Sticks to Its Buy Rating for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
Bernstein Analyst forecast on HK:6990
Rebecca Liang
Bernstein
Bernstein
HK$545→HK$526
Buy
1.15%
Upside
Reiterated
03/26/26
Bernstein Remains a Buy on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
Jefferies Analyst forecast on HK:6990
Unknown Analyst
Jefferies
Not Ranked
Jefferies
HK$520
Buy
0.00%
Upside
Reiterated
03/25/26
Jefferies Remains a Buy on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
CICC Analyst forecast on HK:6990
Unknown Analyst
CICC
Not Ranked
CICC
HK$550
Buy
5.77%
Upside
Reiterated
03/25/26
CICC Sticks to Its Buy Rating for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
BOCOM International Holdings Company Analyst forecast on HK:6990
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
HK$530
Buy
1.92%
Upside
Reiterated
03/25/26
BOCOM International Holdings Company Sticks to Its Buy Rating for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
CMB International Securities Analyst forecast on HK:6990
Jill Wu
CMB International Securities
CMB International Securities
HK$498.55→HK$507.11
Buy
-2.48%
Downside
Reiterated
03/25/26
Kelun-Biotech: Transitioning to Commercial Growth with sac-TMT as a Key Value Driver Supporting a Sustained Buy Rating
Huatai Securities Analyst forecast on HK:6990
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
HK$576.7
Buy
10.90%
Upside
Reiterated
03/24/26
Huatai Securities Keeps Their Buy Rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
Guotai Haitong Analyst forecast on HK:6990
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
HK$529.97
Buy
1.92%
Upside
Reiterated
03/24/26
Guotai Haitong Keeps Their Buy Rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
Citi Analyst forecast on HK:6990
Unknown Analyst
Citi
Not Ranked
Citi
HK$560
Buy
7.69%
Upside
Reiterated
03/24/26
Citi Sticks to Their Buy Rating for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
J.P. Morgan Analyst forecast on HK:6990
Yang Huang
J.P. Morgan
J.P. Morgan
HK$545
Buy
4.81%
Upside
Reiterated
11/24/25
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Receives a Buy from J.P. Morgan
HSBC Analyst forecast on HK:6990
Unknown Analyst
HSBC
Not Ranked
HSBC
HK$549
Buy
5.58%
Upside
Reiterated
10/23/25
Bank of America Securities Analyst forecast on HK:6990
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
HK$522
Hold
0.38%
Upside
Reiterated
10/21/25
Bank of America Securities Remains a Hold on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Nomura Analyst forecast on HK:6990
Unknown Analyst
Nomura
Not Ranked
Nomura
HK$544.42
Buy
4.70%
Upside
Reiterated
05/22/26
Citic Securities Analyst forecast on HK:6990
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$544
Buy
4.62%
Upside
Reiterated
05/22/26
UBS Analyst forecast on HK:6990
Unknown Analyst
UBS
Not Ranked
UBS
HK$625
Buy
20.19%
Upside
Reiterated
05/21/26
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Receives a Buy from UBS
Shenwan Hongyuan Analyst forecast on HK:6990
Unknown Analyst
Shenwan Hongyuan
Not Ranked
Shenwan Hongyuan
HK$560
Buy
7.69%
Upside
Reiterated
03/26/26
Shenwan Hongyuan Sticks to Its Buy Rating for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
Bernstein Analyst forecast on HK:6990
Rebecca Liang
Bernstein
Bernstein
HK$545→HK$526
Buy
1.15%
Upside
Reiterated
03/26/26
Bernstein Remains a Buy on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
Jefferies Analyst forecast on HK:6990
Unknown Analyst
Jefferies
Not Ranked
Jefferies
HK$520
Buy
0.00%
Upside
Reiterated
03/25/26
Jefferies Remains a Buy on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
CICC Analyst forecast on HK:6990
Unknown Analyst
CICC
Not Ranked
CICC
HK$550
Buy
5.77%
Upside
Reiterated
03/25/26
CICC Sticks to Its Buy Rating for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
BOCOM International Holdings Company Analyst forecast on HK:6990
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
HK$530
Buy
1.92%
Upside
Reiterated
03/25/26
BOCOM International Holdings Company Sticks to Its Buy Rating for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
CMB International Securities Analyst forecast on HK:6990
Jill Wu
CMB International Securities
CMB International Securities
HK$498.55→HK$507.11
Buy
-2.48%
Downside
Reiterated
03/25/26
Kelun-Biotech: Transitioning to Commercial Growth with sac-TMT as a Key Value Driver Supporting a Sustained Buy Rating
Huatai Securities Analyst forecast on HK:6990
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
HK$576.7
Buy
10.90%
Upside
Reiterated
03/24/26
Huatai Securities Keeps Their Buy Rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
Guotai Haitong Analyst forecast on HK:6990
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
HK$529.97
Buy
1.92%
Upside
Reiterated
03/24/26
Guotai Haitong Keeps Their Buy Rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
Citi Analyst forecast on HK:6990
Unknown Analyst
Citi
Not Ranked
Citi
HK$560
Buy
7.69%
Upside
Reiterated
03/24/26
Citi Sticks to Their Buy Rating for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
J.P. Morgan Analyst forecast on HK:6990
Yang Huang
J.P. Morgan
J.P. Morgan
HK$545
Buy
4.81%
Upside
Reiterated
11/24/25
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Receives a Buy from J.P. Morgan
HSBC Analyst forecast on HK:6990
Unknown Analyst
HSBC
Not Ranked
HSBC
HK$549
Buy
5.58%
Upside
Reiterated
10/23/25
Bank of America Securities Analyst forecast on HK:6990
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
HK$522
Hold
0.38%
Upside
Reiterated
10/21/25
Bank of America Securities Remains a Hold on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

3 Months
Ziyi ChenGoldman Sachs
Success Rate
3/4 ratings generated profit
75%
Average Return
+15.43%
Copying Ziyi Chen's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +15.43% per trade.
1 Year
Ziyi ChenGoldman Sachs
Success Rate
3/4 ratings generated profit
75%
Average Return
+73.25%
Copying Ziyi Chen's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +73.25% per trade.
2 Years
Ziyi ChenGoldman Sachs
Success Rate
3/4 ratings generated profit
75%
Average Return
+62.40%
Copying Ziyi Chen's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +62.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6990 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
5
11
11
12
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
11
11
12
3
In the current month, 6990 has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 6990 average Analyst price target in the past 3 months is 547.77.
Each month's total comprises the sum of three months' worth of ratings.

6990 Financial Forecast

6990 Earnings Forecast

Next quarter’s earnings estimate for 6990 is HK$0.27 with a range of HK$0.27 to HK$0.27. The previous quarter’s EPS was -HK$1.05. 6990 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 6990 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 6990 is HK$0.27 with a range of HK$0.27 to HK$0.27. The previous quarter’s EPS was -HK$1.05. 6990 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 6990 has Performed in-line its overall industry.

6990 Sales Forecast

Next quarter’s sales forecast for 6990 is HK$1.27B with a range of HK$1.27B to HK$1.27B. The previous quarter’s sales results were HK$1.21B. 6990 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 6990 has Performed in-line its overall industry.
Next quarter’s sales forecast for 6990 is HK$1.27B with a range of HK$1.27B to HK$1.27B. The previous quarter’s sales results were HK$1.21B. 6990 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 6990 has Performed in-line its overall industry.

6990 Stock Forecast FAQ

What is HK:6990’s average 12-month price target, according to analysts?
Based on analyst ratings, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s 12-month average price target is 547.77.
    What is HK:6990’s upside potential, based on the analysts’ average price target?
    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has 5.34% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H a Buy, Sell or Hold?
          Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has a consensus rating of Strong Buy, which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s share price target?
            The average share price target for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H is 547.77. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$625.00 ,and the lowest forecast is HK$507.11. The average share price target represents 5.34% Increase from the current price of HK$520.
              What do analysts say about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H?
              Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H?
                To buy shares of HK:6990, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.